Spyre Therapeutics (SYRE) Interest & Investment Income (2015 - 2026)
Spyre Therapeutics (SYRE) reported Interest & Investment Income of $7.0 million for Q1 2026, up 7.73% on a YoY basis from $6.5 million in Q1 2025, and down 2.02% quarter-over-quarter from $7.1 million in Q4 2025.
Spyre Therapeutics (SYRE) Interest & Investment Income (2015 - 2026) Analysis & Trends
Spyre Therapeutics has reported Interest & Investment Income for 12 years, with the latest figure at $7.0 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 7.73% year-over-year to $7.0 million; the trailing twelve-month figure through Mar 2026 stood at $25.4 million (up 8.62% YoY), and the FY2025 full-year result was $24.9 million, up 16.77% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $7.0 million, down from $7.1 million in the prior quarter.
- The five-year high for Interest & Investment Income was $7.1 million in Q4 2025, with the low at $35000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $3.5 million across 5 years, with a median of $4.4 million in 2024.
- Annual changes were most pronounced in 2024 — Interest & Investment Income surged 1591.43% — and 2025, when it declined 0.78%.
- Spyre Therapeutics' Interest & Investment Income stood at $410000.0 in 2022, then surged by 906.34% to $4.1 million in 2023, then jumped by 39.99% to $5.8 million in 2024, then climbed by 23.6% to $7.1 million in 2025, then declined by 2.02% to $7.0 million in 2026.
- The last three Interest & Investment Income figures came in at $7.0 million (Q1 2026), $7.1 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 597,319.59 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -14.79 Mn |
| 10 | Spyre Therapeutics | 6.95 Bn | 6.95 Bn | - | 7.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.00 Mn |
| Dec 31, 2025 | 7.14 Mn |
| Sep 30, 2025 | 5.38 Mn |
| Jun 30, 2025 | 5.87 Mn |
| Mar 31, 2025 | 6.49 Mn |
| Dec 31, 2024 | 5.78 Mn |
| Sep 30, 2024 | 5.18 Mn |
| Jun 30, 2024 | 5.92 Mn |
| Mar 31, 2024 | 4.43 Mn |
| Dec 31, 2023 | 4.13 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 350,000.00 |
| Mar 31, 2023 | 420,000.00 |
| Dec 31, 2022 | 410,000.00 |
| Sep 30, 2022 | 288,000.00 |
| Jun 30, 2022 | 104,000.00 |
| Mar 31, 2022 | 35,000.00 |
| Dec 31, 2021 | 34,000.00 |
| Sep 30, 2021 | 36,000.00 |
| Jun 30, 2021 | 19,000.00 |